Your browser doesn't support javascript.
loading
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Raizer, J J; Giglio, P; Hu, J; Groves, M; Merrell, R; Conrad, C; Phuphanich, S; Puduvalli, V K; Loghin, M; Paleologos, N; Yuan, Y; Liu, D; Rademaker, A; Yung, W K; Vaillant, B; Rudnick, J; Chamberlain, M; Vick, N; Grimm, S; Tremont-Lukats, I W; De Groot, J; Aldape, K; Gilbert, M R.
Affiliation
  • Raizer JJ; Department of Neurology, Northwestern University, 710 North Lake Shore Drive, Abbott Hall, Room 1123, Chicago, IL, 60611, USA. jraizer@nm.org.
  • Giglio P; James Cancer Hospital, Ohio State University, Columbus, OH, USA.
  • Hu J; Departments of Neurology and Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, USA.
  • Groves M; Austin Brain Tumor Center, Austin, USA.
  • Merrell R; Department of Neurology, NorthShore University Health System, Evanston, USA.
  • Conrad C; Austin Brain Tumor Center, Austin, USA.
  • Phuphanich S; Departments of Neurology and Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, USA.
  • Puduvalli VK; James Cancer Hospital, Ohio State University, Columbus, OH, USA.
  • Loghin M; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Paleologos N; Department of Neurology, Rush University Medical Center, Chicago, USA.
  • Yuan Y; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Liu D; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Rademaker A; Department of Preventive Medicine, Northwestern University, Chicago, USA.
  • Yung WK; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Vaillant B; Dell Medical School, The University of Texas, Austin, USA.
  • Rudnick J; Departments of Neurology and Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, USA.
  • Chamberlain M; Department of Neurology, University of Washington, Seattle, USA.
  • Vick N; Department of Neurology, NorthShore University Health System, Evanston, USA.
  • Grimm S; Department of Neurology, Northwestern University, 710 North Lake Shore Drive, Abbott Hall, Room 1123, Chicago, IL, 60611, USA.
  • Tremont-Lukats IW; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • De Groot J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Aldape K; Department of Pathology, Princess Margaret Cancer Centre, Toronto, Canada.
  • Gilbert MR; Neuro-Oncology Branch, NIH, Bethesda, USA.
J Neurooncol ; 126(1): 185-192, 2016 Jan.
Article in En | MEDLINE | ID: mdl-26476729
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiotherapy / Brain Neoplasms / Glioblastoma / Erlotinib Hydrochloride / Bevacizumab / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Neurooncol Year: 2016 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiotherapy / Brain Neoplasms / Glioblastoma / Erlotinib Hydrochloride / Bevacizumab / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Neurooncol Year: 2016 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos